Effects of benazepril and valsartan on erythropoietin levels in patients with essential hypertension.
- Author:
Lin-lin GUO
1
;
Min LI
;
Ai-hong WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Benzazepines; adverse effects; therapeutic use; Erythropoietin; blood; Female; Hemoglobins; analysis; Humans; Hypertension; blood; drug therapy; Male; Middle Aged; Tetrazoles; adverse effects; therapeutic use; Valine; adverse effects; analogs & derivatives; therapeutic use; Valsartan
- From: Journal of Southern Medical University 2011;31(10):1761-1763
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare effects of valsartan and benazepril on erythropoietin (EPO) levels in essential hypertensive patients with normal renal function.
METHODSSixty essential hypertensive patients were randomly divided into valsartan group (n=30, valsartan 80 mg/day) and benazepril group (n=30, benazepril 10 mg/day). Plasma EPO and hemoglobin (Hb) levels were measured at the start of and at 4 and 8 weeks during the treatments.
RESULTSEPO and Hb levels were all in normal range in the two groups. Valsartan decreased EPO levels from 14.179∓3.214 U/L (baseline) to 12.138∓2.926 U/L (P<0.05) and Hb levels from 144.32∓13.84 g/L (baseline) to 135.16∓14.78 U/L (P<0.05). Benazepril treatment did not resulted in any obvious changes in EPO or Hb levels (P>0.05).
CONCLUSIONValsartan may lower EPO and Hb levels in patients with essential hypertension, while benazepril does not have such effects. The safety of valsartan in anemic hypertensive patients should be further investigated.
